Mucosal exfoliation as a selective reaction to etoricoxib. (31st August 2016)

• Record Type: Journal Article
• Authors: Patanè, M.; Isola, S.; Gangemi, S.; Minciullo, P. L.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 41:Number 6(2016:Dec.)
• Page Start: 722
• Page End: 724
• Publication Date: 2016-08-31
• Subjects: adverse effect -- adverse event -- coxibs -- drugs -- non‐steroidal anti‐inflammatory; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12445
• Languages: English
• ISSNs: 0269-4727

Abstract

Summary: What is known and objective: Etoricoxib is a non‐steroidal anti‐inflammatory drug (NSAID) that inhibits the inducible cyclooxygenase (COX‐2) with a good safety profile. We describe the first case of two mucosal adverse events to etoricoxib in the same patient. Case description: Our patient developed stomatitis with mucosal exfoliation after etoricoxib assumption. Some months later, after a new etoricoxib intake, she presented with vaginal burning, tongue angioedema and erosions, oral exfoliation and wheals on the hands. A provocation test with diclofenac was negative. What is new and conclusion: The peculiarities of our case are the rare clinical manifestation and the selective hypersensitivity to COX‐2 inhibitor with tolerance to a non‐selective NSAID. Abstract : Tongue angioedema with erosions and exfoliation of the oral mucosa as a selective hypersensitive reaction to COX‐2 inhibitor.